Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2008, vol. 17, nr 4, July-August, p. 379–386

Publication type: editorial article

Language: English

Cellular and Intercellular Signaling in Rheumatoid Arthritis – New Therapeutic Targets

Międzykomórkowe i wewnątrzkomórkowe szlaki sygnalizacyjne w reumatoidalnym zapaleniu stawów – nowe możliwości terapeutyczne

Jacek Szechiński1,, Magdalena Szmyrka−Kaczmarek1,, Beata Gruszecka1,

1 Department of Rheumatology and Internal Diseases Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Contemporary therapeutic methods in rheumatoid arthritis are based on selective inhibition of proinflammatory cytokines and intercellular interactions. Novel therapeutic agents are low−molecular−weight compounds capable of targeting intracellular signaling pathways. Mitogen−activated protein kinases and transcription factor NF−κB are presented as attractive potential targets of anti−rheumatic therapy.

Streszczenie

Współczesne leczenie reumatoidalnego zapalenia stawów opiera się na celowanym hamowaniu działania cytokin prozapalnych i interakcji międzykomórkowych. Celem najnowszych badań jest znalezienie drobnocząsteczkowych substancji zdolnych do ingerencji na poziomie wewnątrzkomórkowych szlaków przekazywania sygnału. Jako potencjalne cele terapeutyczne przedstawiono kinazy aktywowane przez mitogeny oraz czynnik transkrypcyjny NF−κB.

Key words

rheumatoid arthritis, MAP−kinases, NF−κB, signal transduction, TNF−α, therapy

Słowa kluczowe

reumatoidalne zapalenie stawów, MAP−kinazy, NF−κB, przekazywanie sygnału, TNF−α, leczenie

References (19)

  1. Edwards JC, Szczepański L, Szechiński J et al.: Efficacy of B−cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(24), 2572–2581.
  2. Mease PJ, Revicki DA, Szechiński J et al.: Improved health−related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose−Ranging Assessment: International Clinical Evaluation of Rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol 2008, 35, 20–30.
  3. Kremer JM, Genant HK, Moreland LWet al.: Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis: a randomized trial. Ann Int Med 2006, 144, 865–876.
  4. Foxwell B, Andreakos E, Brenan F et al.: Prospects for the development of small molecular weight compounds to replace anti−tumour necrosis factor biological agents. Ann Rheum Dis 2003, 62 (Suppl II), ii90–ii93.
  5. Piecyk M, Anderson P: Signal transduction in rheumatoid arthritis. Best Pract Res Clin Rheum 2001, 15, 789–803.
  6. Karin M: Mitogen activated protein kinases as targets for development of novel anti−inflammatory drugs. Ann Rheum Dis 2004, 63, 62–64.
  7. Westra J, Limburg PC, de Boer P et al.: Effects on RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis 2004, 63, 1453–1459.
  8. Hammaker D, Sweeney S, Firestein GS: Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis 2003, 62, 86–89.
  9. Sweeney SE, Firestein GS: Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006, 65 (Suppl III), iii83–iii88.
  10. Verma IM: Nuclear factor (NF)−κB proteins: therapeutic targets*. Ann Rheum Dis 2004, 63 (Suppl II), ii57–ii61.
  11. Strickland I, Ghosh S: Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006, 65 (Suppl III), iii75–iii82.
  12. Hatada EN, Nieters A, Wulczyn FG, Naumann M, Mayer R, Nucifora G et al.: The ankyrin repeat domains of the NF−kappa B precursor p105 and the protooncogen bcl−3 act as specific inhibitors of NF−kappa B DNA binding. Proc Natl Acad Sci USA 1992, 89, 2489–2493.
  13. Ghosh S, May MJ, Kopp EB: NF−kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16, 225–260.
  14. Hayden MS, Ghosh S: Signalling to NF−kappaB. Genes Dev 2004, 18, 2195–2224.
  15. Poyet JL, Srnivasula SM, Lin JH, Fernandes−Alnemri T, Yamaoka S, Tsichlis PN, et al.: Activation of the kappa B kinases by RIP via IKKgamma/NEMO−mediated oligomerization. J Biol Chem 2000, 275, 37966–37977.
  16. Tarassishin L, Horwitz MS: Sites on FIP−3 (NEMO/IKKgamma) essential for its phosphorylation and NF−κB modulating activity. Biochem Biophys Res Commun 2001, 285, 555–560.
  17. Carter RS, Geyer BC, Xie M, Acevedo−Suarez CA, Ballard DW: Persistent activation of NF−kappa B by the tax transforming protein involves chronic phosphorylation of IκB kinase subunits IKKbeta and IKKgamma. J Biol Chem 2001, 276, 2445–2448.
  18. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS et al.: NF−κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998, 95, 13859–13864.
  19. Campbell IK, Gerondakis S, O’Donell K, Wicks IP.: Distinct roles for the NF−κB1 (p50) and c−Rel transcription factors in inflammatory arthritis. J Clin Invest 2000, 105, 1799–1806.
© Wroclaw Medical University